1. Kaprin A.D., Starinskiy V.V., Petrova G.V. (eds.). Malignant neoplasms in Russia in 2016 (morbidity and mortality). Moscow: P. A. Gertsen MROI branch of the FSBI «NMRC of Radiology of the Ministry of Health of the Russian Federation; 2018. 250 c. (In Russ.) Available at: http://www.oncology.ru/service/statistics/malignant_tumors/2016.pdf.
2. Jackman D.M., Zhang Y., Dalby C., Nguyen T., Nagle J., Lydon C.A. et al. Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract. 2017;13(4):e346-e352. doi: 10.1200/JOP.2017.021741.
3. Zhao D., Chen X., Qin N., Su D., Zhou L., Zhang Q. et al. The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer. Sci Rep 2017;12:40374. doi: 10.1038/srep40374.
4. Zhang Y.L., Yuan J.Q., Wang K.F., Fu X.H., Han X.R., Threapleton D. et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993. doi: 10.18632/oncotarget.12587.
5. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C. et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer